Regulatory Briefs: U.K. Trials Database; Hospitals Seek UDI Rule; FDA Workshops

The U.K.’s National Health Service is requiring all U.K. trials to be registered in a clinical trial database. Five influential hospital systems urge the White House to release the UDI final rule. FDA schedules metabolic disease workshop. More regulatory news.

The Health Research Authority, an arm of the U.K.’s National Health Service, is implementing plans to make registration in a publicly accessible clinical trial database a condition of gaining approval from an ethics committee starting Sept. 30. In a Sept. 11 announcement, Janet Wisely, chief executive of HRA, said, “We are fully committed to the principles of transparency in health research. Including a requirement for registration as a condition of the favorable ethical opinion is a significant step towards this.” Failure to register will be a breach of good research practice. The mandated trial registration will initially apply to clinical trials of medical devices and investigational medicinal products. HRA expects all studies to be registered when the first patient is recruited, and will be considered breached if trials aren’t registered within six weeks of patient enrollment. The group expects current and previous studies as well as future studies to be registered in the database.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Italy’s IMQ Designated As 15th Notified Body For IVDs

 

Ireland’s NSAI reinstated under IVD Regulation designation list

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

 
• By 

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?

More from Policy & Regulation

Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&D

 
• By 

Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

 
• By 

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.